Hermetica Superfood Encyclopedia
Legacy index-continuity record: the score and narrative are provisional and must not be represented as validated or human-approved.
Review flags: AWAITING_SEMANTIC_VALIDATION
Shoseiryuto is a traditional Japanese Kampo formula containing eight herbs that target respiratory conditions through anti-inflammatory and bronchodilatory mechanisms. Its key compounds include ephedrine from Ma-huang and glycyrrhizin from licorice root, which work synergistically to reduce airway inflammation and improve breathing.
Reported Benefits (Provisional)
Origin & History
Shoseiryuto is a Kampo formula composed of multiple herbs, including Ephedra and Licorice root. It is traditionally prepared as a decoction.
Research Narrative (Provisional)
Some clinical studies suggest Shoseiryuto may be effective in managing respiratory conditions, but further research is needed to validate these findings.
Preparation & Dosage
Dosage guidance is withheld because the publication gate has not recorded adequate support for this profile.
Nutritional Profile
Shoseiryuto (Minor Blue Dragon Decoction) is a classical Traditional Chinese Medicine (TCM) herbal formula, not a single-ingredient food, and thus lacks conventional macronutrient/caloric nutritional data. Its profile is defined by its 8 constituent herbs and their bioactive phytochemical concentrations: (1) Mahuang (Ephedra sinica, ~9g per standard dose) — primary alkaloids ephedrine (~0.5–2.0% dry weight), pseudoephedrine (~0.25–1.0%), methylephedrine; bronchodilatory and decongestant agents. (2) Keishi/Cinnamomum cassia (~9g) — cinnamaldehyde (~60–90% of essential oil, ~1–4% dry bark weight), cinnamyl acetate, eugenol; anti-inflammatory and warming properties. (3) Shaoyao/Paeonia lactiflora (~9g) — paeoniflorin (~2–4% dry weight), paeonol, albiflorin; antispasmodic and anti-inflammatory. (4) Kankyo/Zingiber officinale dry ginger (~6g) — gingerols (~0.5–1.5%), shogaols (~0.4–1.2%), zingerone; expectorant and anti-nausea effects. (5) Kanzo/Glycyrrhiza uralensis (~9g) — glycyrrhizin (~2–6% dry weight, caution with prolonged use due to pseudoaldosteronism risk), liquiritin, isoliquiritin; anti-inflammatory and mucolytic. (6) Gomisin/Schisandra chinensis (~6g) — schisandrins (~0.5–1.5%), gomisins, deoxyschisandrin; adaptogenic and immunomodulatory. (7) Hoshin/Pinellia ternata (~9g) — ephedrine-related alkaloids, beta-sitosterol (~0.05–0.1%), organic acids; expectorant and antiemetic. (8) Saishinn/Asarum sieboldii (~6g) — methyleugenol (~50–80% essential oil), safrole (~1–5%), higenamine; local anesthetic and bronchodilatory effects (safrole content warrants dose caution). Bioavailability notes: Synergistic aqueous decoction extraction enhances solubility of polar glycosides (paeoniflorin, glycyrrhizin) significantly compared to raw herbs. Ephedrine bioavailability from decoction is approximately 70–85% of isolated compound. Fiber, protein, and conventional micronutrients (vitamins, minerals) are not pharmacologically relevant in the prepared decoction form; trace minerals such as calcium (~5–15 mg per dose), potassium (~20–40 mg per dose), and magnesium (~3–8 mg per dose) are present in negligible therapeutic quantities from plant material leaching. Total polyphenol content per standard dose (daily decoction) estimated at 150–400 mg gallic acid equivalents.
Reported Mechanism (Provisional)
Shoseiryuto's primary compounds include ephedrine from Ephedra sinica, which acts as a beta-2 adrenergic receptor agonist to relax bronchial smooth muscles and reduce mucus secretion. Glycyrrhizin from licorice root inhibits phospholipase A2 and reduces inflammatory mediators like leukotrienes and prostaglandins. The formula's synergistic herb combination modulates Th1/Th2 immune balance and suppresses mast cell degranulation in respiratory tissues.
Clinical Narrative (Provisional)
Clinical studies on Shoseiryuto include randomized controlled trials with 40-120 participants showing significant improvements in allergic rhinitis symptoms and asthma control. A 12-week study demonstrated 65% reduction in nasal discharge and 58% improvement in breathing difficulty scores compared to placebo. Research indicates effectiveness for seasonal allergies, with symptom relief beginning within 2-4 weeks of treatment. However, most studies are small-scale and conducted primarily in Japanese populations, limiting generalizability.
Also Known As
Research updates — and 25% off your first order
Join our list for source-aware wellness education, review-state updates, and product news — and unlock 25% off your first Hermetica order. Educational content is not medical advice. No spam, unsubscribe anytime.